Beam Q1 net loss $109.3M; cash $1.2B after $500M financing; clinical milestones hit

Beam Therapeutics Inc.

2025-Q1 EPS reported -$1.24 revenue$7,470,000

Net loss $109.3M ($1.24/share) vs $98.7M ($1.21/share) Q1 2024; R&D spend $98.8M.
Cash $1.2B including $500M financing; runway into 2028.
First patient dosed for BEAM-301 in GSDIa; IND cleared for BEAM-302 in AATD.
BEAM-101 updated data accepted at EHA June 2025; aim to dose 30 SCD patients by mid-2025.
BEAM-302 fourth cohort dosing started; further data expected H2 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.